Yujie Ren

Prof. Yujie Ren


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MLMei-Lin Li
Mei-Lin Li
YRYujie Ren
Yujie Ren
MDMing-Hui Dong
Ming-Hui Dong
WRWei-Xin Ren
Wei-Xin Ren

27 March 2019 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CZCuihua Zhang
Cuihua Zhang
QLQunlin Li
Qunlin Li
LMLingwei Meng
Lingwei Meng
YRYujie Ren
Yujie Ren
The extrapyramidal side effects of schizophrenia treatment can be significantly reduced by simultaneously targeting dopamine D2 and serotonin 5-HT2A receptors. In this study, three-dimensional quantitative structure–activity relationship (3D-QSAR) models of D2 receptor (CoMFA-1, q2 = 0.767, r2 = 0.969; CoMSIA-1, q2 = 0.717, r2 = 0.978) and 5-HT2A receptor antagonists (CoMFA-2, q2 = 0.703, r2 = 0.946; CoMSIA-2, q2 = 0.675, r2 = 0.916) were successfully constructed using 35 tetrahydropyridopyrimidinone derivatives. Topomer CoMFA and HQSAR models were then constructed to further validate and supplement above models. Results showed that all models had good predictive power and stability. Contour map analysis revealed that the electrostatic and hydrophobic fields played vital roles in the bioactivity of dual antagonists. Molecular docking and molecular dynamic studies also suggested that the hydrogen bonding, electrostatic and hydrophobic interactions played key roles in the formation of stable binding sites. Meanwhile, several key residues like ASP114, TRP100, PHE389 of dopamine D2 receptor and ASP134, PHE328, TRP324 of serotonin 5-HT2A receptor were identified. Based on above findings, seven compounds were obtained through bioisostere replacement and ten compounds were designed by contour map analysis, in which the predicted activity of compounds S6 and DS2 were equivalent to that of the template compound 15. 3D-QSAR and ADMET predictions indicated that all newly designed compounds had great biological activity and physicochemical properties. Moreover, based on the best pharmacophore model, four compounds (Z1, Z2, Z3 and Z4) with new backbones were obtained by virtual screening. Overall, this study could provide theoretical guidance for the structural optimization, design and synthesis of novel dopamine D2 and serotonin 5-HT2A receptors dual antagonists. Communicated by Ramaswamy H. Sarma

13 November 2018 in MedChemComm
Verified
Journal Article
Closed access
PDF file
SHShanshan Huang
Shanshan Huang
KFKairui Feng
Kairui Feng
YRYujie Ren
Yujie Ren
Matrix metalloproteinase-13 (MMP-13) is an attractive drug target for the treatment of osteoarthritis (OA). In this study, a series of quinazolinone derivatives as MMP-13 inhibitors were firstly systematically studied using QSAR, molecular docking and molecular dynamics (MD) simulation. The reliable CoMFA (q2 = 0.646, r2 = 0.992, Rpred 2 = 0.829) and CoMSIA (q2 = 0.704, r2 = 0.992, Rpred 2 = 0.839) models were constructed and verified by the Topomer CoMFA model. Results of contour maps indicated that the electrostatic, hydrophobic and H-bond acceptor fields primarily influenced the activity of MMP-13 inhibitors in the models. Several key residues (Ala238, Thr245, Thr247, Met253, Asn215 and Lys140) were identified as important factors to improve the activity and stability of the inhibitor through hydrogen bonding and electrostatic interaction. Based on these results, eight novel quinazolinones (D1–D8) were further designed. Additionally, all designed compounds showed good pharmacokinetic properties by ADMET predictions. Compounds D3 and D8 exhibited excellent predictive activity, and the 10 ns MD simulations analysis revealed that the hydrogen bonding interaction with residues (Ser250 and Gly248) was enhanced, and the small group in R2 and U-shaped conformation was of pivotal importance. These results provided strong guidance for the discovery and design of novel potential MMP-13 inhibitors.


16 November 2016 in Chemical Research in Chinese Universities
Verified
Journal Article
Closed access
PDF file
HYHaoran Yang
Haoran Yang
YRYujie Ren
Yujie Ren
XGXiaodong Gao
Xiaodong Gao
YGYonghong Gao
Yonghong Gao

15 December 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
XPXiu Xiu Peng
Xiu Xiu Peng
KFKai Rui Feng
Kai Rui Feng
YRYujie Ren
Yujie Ren
The forced expression of phosphoinositide 3-kinase δ (PI3Kδ) in B cells was found to be oncogenic, rendering PI3Kδ an attractive drug target for chronic lymphocytic leukaemia. This study aimed to systemically explore the interaction mechanism of novel quinazolinone scaffold-based derivatives as PI3Kδ inhibitors using 3D-QSAR, molecular docking, pharmacophore model and molecular dynamics (MD) simulations. The 3D-QSAR models CoMFA, CoMSIA and Topomer CoMFA were established to discover critical structural factors affecting PI3Kδ inhibitory activity. The models showed suitable reliabilities (q2 0.741, 0.712 and 0.711) and predictive abilities (rpred 2 0.851, 0.738 and 0.828, respectively). Contour maps indicated that the bioactivity of PI3Kδ inhibitor was affected most by electrostatic and hydrophobic fields. The Surflex-Dock and pharmacophore model result showed that enhancing the H-bond interaction of the key substituents around the 2- and 4-positions of pyrimidine with Glu826, Val828 and Asp911, as well as the electrostatic interactions of substituents around the 3-position of benzene with Ser831, Asp832 and Asn836, significantly affected the improvement in the activity and stability of the inhibitor. Based on these results, 10 novel PI3Kδ inhibitors with higher predicted activity and binding affinity were designed by introducing the heterocycles pyrrolopyridine or purine. 10 ns MD simulations further study the stable docking conformation of designed compounds, which showed strong hydrogen bond interactions with key residues Ser831 and Asp832 in a propeller-like fashion. These results provided strong guidance for the discovery and optimization of novel potent PI3Kδ selective inhibitors.